The non-small-cell lung cancer (NSCLC) subtype, accounting for the majority of the cases, includes adenocarcinoma and is often treated with tyrosine kinase inhibitors targeting epidermal growth factor receptor (EGFR)-activating mutations. The gene discussed is EGFR; the disease is adenocarcinoma.